2016 China's top ten pharmaceutical biotechnology progress selection results.

On December 24, 2016, the results of the "Top Ten Progress Selections of China's Pharmaceutical Biotechnology 2016" organized by the China Pharmaceutical Biotechnology Association and the China Pharmaceutical Biotechnology Journal were announced at the Hangzhou Economic Development Zone.
attending the event were selected panel of experts on behalf of Chen Zhinan, Zhong Shizhen, the leader of the organizers and contractors, the central and local nearly ten media reporters.
2016 is the opening year of the 13th Five-Year Plan, biomedicine has been listed as one of the key areas of development, and a large number of new policies have been introduced and implemented to continuously promote the healthy, transparent and orderly development of the industry.
China Pharmaceutical Biotechnology Association through the "Top Ten Progresses of China's Pharmaceutical Biotechnology of the Year" selection activities to comb and record the development of the industry, insight into the development trend, promote the development of the entire industry in depth.
, according to the editor-in-chief understand that this activity is divided into recommendation declaration, public selection, expert review and press release 4 links.
Of these, 21 candidates emerged from the recommendation declaration to enter the public voting process, the website and WeChat public vote opened at the same time, in just 7 days to get the enthusiastic participation of more than 50,000 peers, in order to reflect the professionalism and authority of the selection, all candidates will be submitted to the relevant fields of 10 academicians for expert review, according to whether the project has outstanding technological innovation, economic or social benefits, promote the industry's scientific and technological progress and other criteria for a private vote;
The top ten progress results of China's medical biotechnology in 2016 are: 1. The monolithic bone marrow transplantation technology system has become the "Beijing Program" for leukemia treatment China's original single-fold bone marrow transplantation technology system, which has greatly improved the success rate of leukemia bone marrow transplantation, which provides a solution to the problem of insufficient supply of leukemia bone marrow transplantation, which is now widely used in many countries.
was officially named the "Beijing Program" for leukemia treatment by the World Bone Marrow Transplant Association in 2016 and recommended as a reliable transplant solution for the global lack of all-in-one donor.
2. Long-acting interferon has been approved for listing as a new Class I drug for the treatment of viral hepatitis developed by China.
the drug by major new drug creation national science and technology major special long-term support.
the preparation antiviral effect is better, half-life is longer, only need to inject once a week, easy to use.
treatment for hepatitis C is comparable to that of imported products, but at a low price.
successfully listed the drug, breaking the international monopoly of similar drugs, greatly reducing medical costs, with better economic and social benefits.
3. Compaxip eye injection directly into the FDA Phase III clinical study Compaq eye injection in 2013 after the market, with good efficacy, safety and low cost has been widely recognized by the market, breaking the international monopoly.
has now been granted direct access to Phase III clinics in the United States by the FDA, and the project has been supported by major new drug creation national science and technology major projects, opening up a new situation for the internationalization of innovative biopharmaceased drugs in China.
4. The broad-spectrum tumor marker thermospock protein 90 alpha (Hsp90 alpha) has been approved for use in clinical tumor marker thermospock protein 90 alpha (Hsp90 alpha) approved by the State Food and Drug Administration for the detection of patients with clinical liver cancer, and a breakthrough has been made.
is another marker after the detection of hepatitis A protein markers in patients with liver cancer.
is of great clinical value to the monitoring, evaluation and guidance of liver cancer patients.
5. Respiratory pathogen disc chip system has been successfully developed respiratory pathogen disc chip system has been successfully developed.
testing kit obtained a medical device certificate in February 2016.
the kit has the characteristics of fast detection, accurate and sensitive, and provides an effective tool for the rapid diagnosis and treatment of infectious diseases and the response to major sudden diseases.
. China's microbiome big data search engine online China's microbiome big data search engine MSE online, so that the microbiome for intelligent search and big data mining become a reality.
MSE can list "catalogues" of bacterial structure or functional similarity for a large number of samples.
also released the analysis software Paralel-META 3, which analyzes the structure and function of unknown microbiome samples and provides in-depth comparative analysis of database search results.
7. The use of stem cell technology to develop artificial blood breakthrough After 10 years of research and development, Chinese researchers have established a key technology system of stem cell procedural high-efficiency amplification and blood-directed induction differentiation, improved the efficiency of stem cell directional induction differentiation and amplification, made a new breakthrough in the large-scale preparation of red blood cells, the amplification rate is significantly better than the previous technical level, so that China's stem cell preparation "artificial blood" technology into the international advanced ranks.
8. New Deal on Drug Production: Pilot Drug Listing Licensor System The Drug Listing Licensor System, that is, the separation of drug listing license from production license.
a drug market license may produce their own products, or they may entrust qualified production enterprises to "work on behalf of" to obtain a drug market license.
is an important reform of China's drug management system.
the system reduces duplication of construction, improves the utilization rate of production equipment, and promotes the specialization of division of labor.
9. Shenzhen National Gene Bank Opened Shenzhen National Gene Bank is positioned as "three libraries and two platforms", that is, gene information database, biological sample resource bank and bio-living library and digital platform, synthesis and gene editing platform.
the gene pool focuses on biomedicine, bio-agriculture, microbiology and marine life, shortening the application cycle from basic scientific research to scientific and technological achievements.
comprehensive capacity of Shenzhen National Gene Bank has reached the forefront of the world.
10. Self-regulatory norms for the quality management of cell preparation Issued by the China Pharmaceutical Biotechnology Association organization industry backbone enterprises and experts with reference to GMP, Stem Cell Clinical Research Management Measures (Trial) and Stem Cell Preparation Quality Control and Preclinical Research Guidelines (Trial), as well as relevant guidelines of relevant foreign organizations, repeatedly revised the formation of the "Immune Cell Preparation Quality Management Self-Regulation Code" and "Stem Cell Preparation Quality Management Code."
the specification puts forward the basic principles for preparation agencies to prepare immune cells and stem cells, provides reference for government and departmental regulatory decision-making, and provides a basis for research institutes and enterprises to develop new products.
source: China Pharmaceutical Biotechnology Association.